Clinical trial
A Phase 2a, Multi-Center, Randomized, Parallel Group, Double Blind and Placebo-controlled Clinical Trial to Assess Safety and Tolerability as Well as Explorative Efficacy of the Orthosteric Selective Muscarinic M1 Agonist NSC001 in Mild to Moderate Alzheimer's Disease
NCT06995573 is registered in ClinicalTrials.gov with NSC-Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a, Multi-Center, Randomized, Parallel Group, Double Blind and Placebo-controlled Clinical Trial to Assess Safety and Tolerability as Well as Explorative Efficacy of the Orthosteric Selective Muscarinic M1 Agonist NSC001 in Mild to Moderate Alzheimer's Disease
- Lead sponsor
- NSC-Therapeutics
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- August 25, 2025
- Completion date
- September 30, 2026
- Enrollment
- 90 (estimated)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.